Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma

Nowakowski, Grzegorz S;Yoon, Dok Hyun;Mondello, Patrizia;Joffe, Erel;Peters, Anthea;Fleury, Isabelle;Greil, Richard;Ku, Matthew;Marks, Reinhard;Kim, Kibum;Zinzani, Pier Luigi;Trotman, Judith;Sabatelli, Lorenzo;Waltl, Eva E;Winderlich, Mark;Sporchia, Andrea;Kurukulasuriya, Nuwan C;Cordoba, Raul;Hess, Georg;Salles, Gilles

2023-01-01